REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Telomere Stack

Anti-Aging & Longevityintermediate

79

synergy

79
Share
Peptides

2

Avg Daily mcg

10,500

Level

intermediate

Added

May 17, 2026

Overview

The Telomere Stack is a focused two-peptide protocol targeting chromosomal maintenance and cellular rejuvenation. Epithalon''s primary mechanism is activation of the catalytic subunit of telomerase (hTERT), the enzyme responsible for adding TTAGGG repeats to chromosome ends. In cell culture studies, Epithalon-treated fibroblasts showed a 33% increase in telomere length and extended their replicative lifespan by approximately 10 additional cell divisions beyond the Hayflick limit. In Khavinson''s longitudinal human studies, elderly patients receiving Epithalon showed normalized melatonin production, improved immune markers, and reduced all-cause mortality compared to controls over 6-12 year follow-up periods. GHK-Cu contributes to this stack through its remarkable gene expression modulation profile. Genome-wide studies reveal that GHK-Cu resets expression of numerous aging-related genes toward youthful patterns, including genes involved in DNA repair (GADD45A, XRCC1), antioxidant defense (SOD3, glutathione peroxidase), and anti-inflammatory pathways (IL-6 suppression, TGF-beta modulation). This transcriptomic "resetting" effect complements Epithalon''s telomere maintenance by ensuring that cells with preserved telomere length also maintain youthful functional capacity rather than persisting in a senescent-adjacent state. The stack follows a cyclical protocol: Epithalon is administered daily for 10 days, then discontinued for 4-6 months while GHK-Cu continues daily. This cycling is based on Khavinson''s research showing that telomerase activation occurs during the treatment window and persists for months afterward, making continuous administration unnecessary. GHK-Cu provides ongoing cellular maintenance between Epithalon cycles. This is one of the more conservative longevity stacks, suitable for individuals who want to address cellular aging biomarkers with well-characterized peptides.

Dosing Protocol

Epithalon

daily (10-day cycle)· subcutaneous

Read more about Epithalon →

10,000 mcg

per dose

GHK-Cu

Every day· subcutaneous

Read more about GHK-Cu →

500 mcg

per dose

Goals & Evidence

Telomere extensionCellular agingSkin healthDNA repairLongevity
Evidence tier:Animal Studies

Warnings

  • Epithalon is Cat 2. Telomere extension claims based on in-vitro and animal studies. Human longevity data is observational only.

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.